R-GEMOX方案二线治疗弥漫大B细胞淋巴瘤的临床疗效观察  

Clinical effect of R-GEMOX scheme for second-line therapy of diffuse large B-cell lymphoma

作　　者：郑锐年[1] 林顺欢[1] 林钦雄[1] 刘淳[1] 卢志斌[1] 

机构地区：[1]广东省东莞市人民医院肿瘤内科,广东东莞523000

出　　处：《中国医学工程》2016年第3期9-11,共3页China Medical Engineering

摘　　要：目的观察利妥昔单抗联合盐酸吉西他滨和奥沙利铂(R-GEMOX)方案二线治疗弥漫大B细胞淋巴瘤的临床疗效。方法将该院2010年1月‐2015年12月收治的50例弥漫大B细胞淋巴瘤患者分为R-ICE组与R-GEMOX组各25例,对比两组的治疗效果与毒副作用。结果 1 R-GEMOX组总有效率为36%,临床获益率为76%;R-ICE组总有效率为32%,临床获益率为72%;两组在总有效率与临床获益率之间比较均无明显差异,不具有统计学意义(P>0.05)。2毒副作用:治疗期间R-GEMOX组的毒副作用发生率为44%;R-ICE组的毒副作用发生率为60%,R-GEMOX组明显低于R-ICE组,差异具有统计学意义(P<0.05)。结论 R-GEMOX在弥漫大B细胞淋巴瘤二线治疗中的近期效果确切,而且患者对不良反应可耐受,可以考虑作为补救性化疗方案在临床中推广应用。【Objective】To observe the clinical efficacy and side effects of rituximab plus gemcitabine and oxaliplatin（R-GEMOX） regimen in second-line therapy for diffuse large B-cell lymphoma.【Methods】The clinical data of 50 cases of B-cell lymphoma admitted in our hospital from January 2010 to December 2015 were retrospectively analyzed, and the patients were divided into rituximab plus ifosfamide, carboplatin and etoposide（R-ICE） group and R-GEMOX group with 25 cases in each. Treatment effect and toxicity evaluation of two groups were compared.【Results】1 The total effi ciency of R-GEMOX group was 36%, and the clinical benefi t rate was 76%; the total effi ciency of R-ICE group was 32%, and the clinical benefi t rate was 72%; there were no signifi cant differences between the two groups in the total effective rate and the clinical benefi t rate（P 〉0.05）. 2 Toxic and side effects： during the treatment period, there were 4 cases of bone marrow suppression and 7 cases of gastrointestinal reaction in the R-GEMOX group, and the incidence of toxic and side effects was 44%; there were 5 cases of bone marrow suppression and 10 cases of gastrointestinal reaction in the R-ICE group, and the incidence of toxic and side effects was 60%; the incidence of toxic and side effects in the R-GEMOX group was signifi cantly lower than that in the R-ICE group（P 〈0.05）.【Conclusion】R-GEMOX has satisfactory defi nite short-term effects in second-line therapy for diffuse large B-cell lymphoma, and the patients can tolerate adverse reactions, which can be considered as a remedy for chemotherapy in the clinical application.

关 键 词：弥漫大B细胞淋巴瘤 吉西他滨 奥沙利铂 

分 类 号：R733.4[医药卫生—肿瘤]